We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-20 of 10,000 results
  1. Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

    Background

    Ezabenlimab (BI 754091) is a humanised monoclonal antibody targeting programmed cell death protein-1. We report results from open-label,...

    Manish R. Patel, Melissa Johnson, ... Lillian L. Siu in Cancer Immunology, Immunotherapy
    Article Open access 30 March 2024
  2. Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors

    Purpose

    This two-part, open-label, non-randomized dose-escalation study aimed to define the maximum tolerated dose (MTD) of BI 836880 (humanized...

    Noboru Yamamoto, Takafumi Koyama, ... Kentaro Yamazaki in Cancer Chemotherapy and Pharmacology
    Article 04 May 2023
  3. A Potential Role for MAGI-1 in the Bi-Directional Relationship Between Major Depressive Disorder and Cardiovascular Disease

    Purpose of Review

    Major Depressive Disorder (MDD) is characterized by persistent symptoms such as fatigue, loss of interest in activities, feelings of...

    Priyanka Banerjee, Khanh Chau, ... Nhat-Tu Le in Current Atherosclerosis Reports
    Article 03 July 2024
  4. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity

    Background

    The study characterizes safety, tolerability, pharmacokinetic and pharmacodynamic profiles of single rising doses of the...

    Susanna Bianzano, Tim Heise, ... Ulrike Gräfe-Mody in Clinical Diabetes and Endocrinology
    Article Open access 15 August 2021
  5. Insulin Rescued MCP-1-Suppressed Cholesterol Efflux to Large HDL2 Particles via ABCA1, ABCG1, SR-BI and PI3K/Akt Activation in Adipocytes

    Purpose

    Intracellular cholesterol imbalance plays an important role in adipocyte dysfunction of obesity. However, it is unclear whether obesity...

    Runlu Sun, Pu Fang, ... Yuling Zhang in Cardiovascular Drugs and Therapy
    Article Open access 19 March 2021
  6. DNA-PKcs promotes cardiac ischemia reperfusion injury through mitigating BI-1-governed mitochondrial homeostasis

    DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a novel inducer to promote mitochondrial apoptosis and suppress tumor growth in a...

    Hao Zhou, Sam Toan, ... Yingmei Zhang in Basic Research in Cardiology
    Article 09 January 2020
  7. The Role of Elastography in Reducing Unnecessary Biopsies in BI-RADS 4a and 4b Breast Lesions

    Many benign breast lesions in the Breast Imaging Reporting and Data System (BI-RADS) 4 category defined by ultrasonography (US) undergo unnecessary...

    Nurşen Toprak, Adem Yokus, ... Zehra Akman Ilik in Indian Journal of Surgery
    Article 27 December 2023
  8. A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro

    Background

    Polo-like kinase 1 (PLK1) is a critical therapeutic target in the treatment of head and neck squamous cell carcinoma (HNSCC). The objective...

    Article Open access 27 March 2024
  9. The effectiveness of a brief intervention for intensive care unit patients with hazardous alcohol use: a randomized controlled trial

    Background

    Screening for hazardous alcohol use and performing brief interventions (BIs) are recommended to reduce alcohol-related negative health...

    Eliisa Nissilä, Marja Hynninen, ... Johanna Hästbacka in Critical Care
    Article Open access 30 April 2024
  10. Breast lesions on MRI in mass and non-mass enhancement: Kaiser score and modified Kaiser score + for readers of variable experience

    Objectives

    To compare the diagnostic performance of three readers using BI-RADS and Kaiser score (KS) based on mass and non-mass enhancement (NME)...

    Jiejie Zhou, Huiru Liu, ... Meihao Wang in European Radiology
    Article 11 July 2024
  11. Open questions on basal insulin therapy in T2D: a Delphi consensus

    Aims

    The revolution in the therapeutic approach to type 2 diabetes (T2D) requires a rethinking of the positioning of basal insulin (BI) therapy. Given...

    Aglialoro Alberto, Anichini Roberto, ... Giuseppina T. Russo in Acta Diabetologica
    Article Open access 20 May 2024
  12. Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models

    Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is endemic to parts of Asia and overexpression of vascular endothelial growth...

    Rachel C.T. Lam, Connie W.C. Hui, ... Brigette B.Y. Ma in Investigational New Drugs
    Article 12 August 2023
  13. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies

    Introduction

    The transient receptor potential canonical (TRPC) ion channels have been implicated in the pathophysiology of major depressive disorder...

    René Fuertig, Markus Goettel, ... Vikas Sharma in CNS Drugs
    Article Open access 29 November 2023
  14. Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey

    This study aimed to assess the incidence, predictors, and outcomes of breakthrough infection (BI) following coronavirus disease (COVID-19)...

    Sakir Ahmed, Latika Gupta, ... Ashima Makol in Rheumatology International
    Article 05 September 2023
  15. Mammographic calcifications undergoing percutaneous biopsy: outcome in women with and without a personal history of breast cancer

    Purpose

    To compare the positive predictive values (PPVs) of BI-RADS categories used to assess pure mammographic calcifications in women with and...

    Valeria Bertani, Nicole Berger, ... Magda Marcon in La radiologia medica
    Article Open access 04 January 2023
  16. Biomechanical Integrity Score of the Female Pelvic Floor for Stress Urinary Incontinence

    Introduction and hypothesis

    This study is aimed at develo** and validating a new integral parameter, the Biomechanical Integrity score (BI-score) of...

    Peter Takacs, Dávid Rátonyi, ... Bence Kozma in International Urogynecology Journal
    Article Open access 13 May 2024
  17. Breast Cancer Screening and BI-RADS Scoring Trends Before and During the COVID-19 Pandemic in an Academic Safety-Net Hospital

    Background

    Little is known about how the COVID-19 pandemic affected screening mammography rates and Breast Imaging Reporting and Data Systems...

    Anna Kobzeva-Herzog, Thomas O’Shea, ... Michael R. Cassidy in Annals of Surgical Oncology
    Article 04 January 2024
  18. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant

    Potent neutralizing antibodies (nAbs) against SARS-CoV-2 are a promising therapeutic against the ongoing COVID-19 pandemic. However, the continuous...

    Mengqi Yuan, Yanzhi Zhu, ... **huang Liu in One Health Advances
    Article Open access 30 April 2023
  19. Characteristics and evaluation of C1 posterior arch variation for transpedicular screw placement between patients with and without basilar invagination

    Background

    C1 transpedicular screw (C1TS) placement provided satisfactory pullout resistance and 3D stability, but its application might be limited in...

    Lu-** Zhou, Chen-Hao Zhao, ... Cai-Liang Shen in European Spine Journal
    Article 02 August 2023
  20. A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)

    Background

    This study investigated whether schedule modification of bi-weekly nanoparticle albumin-bound paclitaxel (nab-PTX) plus ramucirumab (RAM)...

    Ryohei Kawabata, Naoki Izawa, ... Masashi Fujii in Targeted Oncology
    Article 15 April 2023
Did you find what you were looking for? Share feedback.